Metabolix, Inc. Share Price Nasdaq
Equities
US5910188821
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
20/05 | Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index | CI |
15/05 | Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000 | MT |
Sales 2024 * | 1.2M 100M | Sales 2025 * | 2.6M 217M | Capitalization | 1.23M 102M |
---|---|---|---|---|---|
Net income 2024 * | -9M -751M | Net income 2025 * | -11M -918M | EV / Sales 2024 * | 1.02 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.47 x |
P/E ratio 2024 * |
-0.18
x | P/E ratio 2025 * |
-0.16
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Metabolix, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Oliver Peoples
FOU | Founder | 66 | 01/92/01 |
Charles Haaser
DFI | Director of Finance/CFO | 68 | 01/08/01 |
Kristi Snell
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/97/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 01/06/01 | |
Richard Hamilton
BRD | Director/Board Member | 61 | 02/17/02 |
Oliver Peoples
FOU | Founder | 66 | 01/92/01 |
1st Jan change | Capi. | |
---|---|---|
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |